147 related articles for article (PubMed ID: 11182567)
1. In vitro and in vivo evaluation of new radiolabeled neurotensin(8-13) analogues with high affinity for NT1 receptors.
García-Garayoa E; Allemann-Tannahill L; Bläuenstein P; Willmann M; Carrel-Rémy N; Tourwé D; Iterbeke K; Conrath P; Schubiger PA
Nucl Med Biol; 2001 Jan; 28(1):75-84. PubMed ID: 11182567
[TBL] [Abstract][Full Text] [Related]
2. Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors.
García-Garayoa E; Maes V; Bläuenstein P; Blanc A; Hohn A; Tourwé D; Schubiger PA
Nucl Med Biol; 2006 May; 33(4):495-503. PubMed ID: 16720241
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of a new, stabilized neurotensin(8--13) pseudopeptide radiolabeled with (99m)tc.
García-Garayoa E; Bläuenstein P; Bruehlmeier M; Blanc A; Iterbeke K; Conrath P; Tourwé D; Schubiger PA
J Nucl Med; 2002 Mar; 43(3):374-83. PubMed ID: 11884498
[TBL] [Abstract][Full Text] [Related]
4. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
de Visser M; Janssen PJ; Srinivasan A; Reubi JC; Waser B; Erion JL; Schmidt MA; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1134-9. PubMed ID: 12768332
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution and catabolism of (18)F-labeled neurotensin(8-13) analogs.
Bergmann R; Scheunemann M; Heichert C; Mäding P; Wittrisch H; Kretzschmar M; Rodig H; Tourwé D; Iterbeke K; Chavatte K; Zips D; Reubi JC; Johannsen B
Nucl Med Biol; 2002 Jan; 29(1):61-72. PubMed ID: 11786277
[TBL] [Abstract][Full Text] [Related]
6. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.
Achilefu S; Srinivasan A; Schmidt MA; Jimenez HN; Bugaj JE; Erion JL
J Med Chem; 2003 Jul; 46(15):3403-11. PubMed ID: 12852770
[TBL] [Abstract][Full Text] [Related]
7. Stabilization of neurotensin analogues: effect on peptide catabolism, biodistribution and tumor binding.
Bruehlmeier M; Garayoa EG; Blanc A; Holzer B; Gergely S; Tourwé D; Schubiger PA; Bläuenstein P
Nucl Med Biol; 2002 Apr; 29(3):321-7. PubMed ID: 11929702
[TBL] [Abstract][Full Text] [Related]
8. Radionuclide imaging of small-cell lung cancer (SCLC) using 99mTc-labeled neurotensin peptide 8-13.
Zhang K; An R; Gao Z; Zhang Y; Aruva MR
Nucl Med Biol; 2006 May; 33(4):505-12. PubMed ID: 16720242
[TBL] [Abstract][Full Text] [Related]
9. Novel 99mTc-labeled neurotensin analogues with optimized biodistribution properties.
Maes V; Garcia-Garayoa E; Bläuenstein P; Tourwé D
J Med Chem; 2006 Mar; 49(5):1833-6. PubMed ID: 16509599
[TBL] [Abstract][Full Text] [Related]
10. New neurotensin analogue radiolabeled by 99m-technetium as a potential agent for tumor identification.
Emrarian I; Sadeghzadeh N; Abedi SM; Abediankenari S
Chem Biol Drug Des; 2018 Jan; 91(1):304-313. PubMed ID: 28816013
[TBL] [Abstract][Full Text] [Related]
11. Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc.
Nock BA; Nikolopoulou A; Reubi JC; Maes V; Conrath P; Tourwé D; Maina T
J Med Chem; 2006 Jul; 49(15):4767-76. PubMed ID: 16854083
[TBL] [Abstract][Full Text] [Related]
12. Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors.
Alshoukr F; Rosant C; Maes V; Abdelhak J; Raguin O; Burg S; Sarda L; Barbet J; Tourwé D; Pelaprat D; Gruaz-Guyon A
Bioconjug Chem; 2009 Aug; 20(8):1602-10. PubMed ID: 19610615
[TBL] [Abstract][Full Text] [Related]
13. Facile Preparation of a Thiol-Reactive (18)F-Labeling Agent and Synthesis of (18)F-DEG-VS-NT for PET Imaging of a Neurotensin Receptor-Positive Tumor.
Wu Z; Li L; Liu S; Yakushijin F; Yakushijin K; Horne D; Conti PS; Li Z; Kandeel F; Shively JE
J Nucl Med; 2014 Jul; 55(7):1178-84. PubMed ID: 24854793
[TBL] [Abstract][Full Text] [Related]
14. Improving the tumor uptake of 99mTc-labeled neuropeptides using stabilized peptide analogues.
Bläuenstein P; Garayoa EG; Rüegg D; Blanc A; Tourwé D; Beck-Sickinger A; Schubiger PA
Cancer Biother Radiopharm; 2004 Apr; 19(2):181-8. PubMed ID: 15186598
[TBL] [Abstract][Full Text] [Related]
15. Catabolism of neurotensins. Implications for the design of radiolabeling strategies of peptides.
Schubiger PA; Allemann-Tannahill L; Egli A; Schibli R; Alberto R; Carrel-Rémy N; Willmann M; Bläuenstein P; Tourwé D
Q J Nucl Med; 1999 Jun; 43(2):155-8. PubMed ID: 10429510
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targeting.
Jia Y; Shi W; Zhou Z; Wagh NK; Fan W; Brusnahan SK; Garrison JC
Nucl Med Biol; 2015 Nov; 42(11):816-23. PubMed ID: 26302836
[TBL] [Abstract][Full Text] [Related]
17. A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours.
García-Garayoa E; Bläuenstein P; Blanc A; Maes V; Tourwé D; Schubiger PA
Eur J Nucl Med Mol Imaging; 2009 Jan; 36(1):37-47. PubMed ID: 18690434
[TBL] [Abstract][Full Text] [Related]
18. Improved radiosynthesis and preliminary in vivo evaluation of a (18)F-labeled glycopeptide-peptoid hybrid for PET imaging of neurotensin receptor 2.
Maschauer S; Greff C; Einsiedel J; Ott J; Tripal P; Hübner H; Gmeiner P; Prante O
Bioorg Med Chem; 2015 Jul; 23(14):4026-33. PubMed ID: 25691211
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of neurotensin(9-13) analogues exhibiting enhanced human neurotensin receptor binding affinities.
Lundquist JT; Büllesbach EE; Dix TA
Bioorg Med Chem Lett; 2000 Mar; 10(5):453-5. PubMed ID: 10743946
[TBL] [Abstract][Full Text] [Related]
20. Preparation and receptor binding affinities of cyclic C-terminal neurotensin (8-13) and (9-13) analogues.
Lundquist JT; Dix TA
Bioorg Med Chem Lett; 1999 Sep; 9(17):2579-82. PubMed ID: 10498212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
